TP53 mutations were significantly more prevalent in MKShi/ERSlo tumours (34%) than in other subgroups (6%, 12% and 16% in MKSlo/ERShi, MKSlo/ERSlo and MKShi/ERShi, respectively) (p = 8.28 × 10−11) (Supplementary Table 2). The gene discussed is TP53; the disease is neoplasm.